Mike (Przemyslaw) Sapieha

Mike (Przemyslaw) Sapieha has a long and varied work experience. Mike (Przemyslaw) began their career as a Research Biologist at MethylGene Inc. in 1997. In 2010, they joined Universit\u00e9 de Montr\u00e9al as an Assistant Professor, and they were later promoted to Associate Professor and then Full Professor. In 2017, they founded and became the Chief Scientific Officer of SemaThera Inc. Mike (Przemyslaw) also held the role of Interim Director at H\u00f4pital Maisonneuve-Rosemont in 2020. Currently, they are the Chief Scientific Advisor for UNITY Biotechnology.

Mike (Przemyslaw) Sapieha's education history includes a Postdoctoral Fellowship from Harvard University in Retinal Vascular Biology from 2008 to 2010, a Doctor of Philosophy - PhD in Neuroscience from Université de Montréal from 2000 to 2005, a Bachelor of Science - BS in Biochemistry from McGill University from 1995 to 1998, and attendance at Marianopolis College from 1993 to 1995.